G1 Therapeutics (NASDAQ:GTHX) will issue its quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
Shares of G1 Therapeutics (NASDAQ GTHX) opened at $19.69 on Monday. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67.
In related news, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total value of $86,696.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Medimmune Ventures, Inc. sold 133,906 shares of G1 Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.75, for a total transaction of $2,644,643.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 350,458 shares of company stock valued at $6,939,148.
A hedge fund recently bought a new stake in G1 Therapeutics stock. Vanguard Group Inc. purchased a new stake in G1 Therapeutics Inc (NASDAQ:GTHX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 74,000 shares of the company’s stock, valued at approximately $1,291,000. Vanguard Group Inc. owned 5.00% of G1 Therapeutics at the end of the most recent quarter. 52.01% of the stock is owned by hedge funds and other institutional investors.
GTHX has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. BidaskClub raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. raised their price objective on shares of G1 Therapeutics to $30.00 in a research report on Monday, February 5th. Finally, BTIG Research initiated coverage on shares of G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $32.80.
TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/19/g1-therapeutics-gthx-to-release-quarterly-earnings-on-wednesday.html.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.